Efficacy and Tolerability of MlC601 in Patients with Mild to Moderate Alzheimer Disease who were Unable to Tolerate or Failed to Benefit from Treatment with Rivastigmine
Ali Amini Harandi, Farzad Ashrafi, Mojgan Tabatabaei, Askar Ghorbani, Hamidreza Hatamian, Hossein Pakdaman, Manochehr Ilkhani, Koroush Gharagozli, Maziar Shojae, Marjan Asadollahi, Farshid Alaeddini & Seyed Kazem Hosseini · Journal of Advances in Medicine and Medical Research · 2013
Aim: To evaluate the efficacy and tolerability of MLC601 in patients with mild to moderate Alzheimer disease (AD). Study Design: This is an open-label pilot study. Place and Duration of Study: It was conducted at three university referral centres in Iran from September 2009 until...
Open access
Research Article
10.9734/BJMMR/2013/2537